STOCK TITAN

ImmunityBio, Inc. - IBRX STOCK NEWS

Welcome to our dedicated page for ImmunityBio news (Ticker: IBRX), a resource for investors and traders seeking the latest updates and insights on ImmunityBio stock.

ImmunityBio, Inc. (symbol: IBRX) is a pioneering biotechnology company specializing in immuno-oncology and infectious disease treatments. With a focus on activating both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems, ImmunityBio is at the forefront of developing innovative molecular and product platforms.

The company's key platforms include the development of antibody-cytokine fusion proteins, DNA, RNA, and recombinant protein vaccines, as well as cell therapies. ImmunityBio is working on several significant product candidates, such as n-803, aldoxorubicin, and a second-generation adenovirus vector. These platforms are designed to activate natural killer (NK) cells, T cells, tumoricidal macrophages, and memory T cells, providing a comprehensive approach to cancer treatment and infectious disease management.

Anktiva, one of ImmunityBio's leading product candidates, is an IL-15 superagonist antibody-cytokine fusion protein, which enhances the body's immune response against cancer cells. The company's pipeline includes treatments targeting bladder, lung, and colorectal cancers, as well as glioblastoma multiforme (GBM).

Headquartered in the United States, ImmunityBio operates across two geographical segments: the United States and Europe, with key revenue generated from European markets. The company is integrated from discovery and development to commercialization, ensuring a seamless transition of its products from the laboratory to the market.

ImmunityBio has achieved several milestones, including the initiation of pivotal clinical trials and strategic partnerships with leading research institutions. These accomplishments underscore the company's commitment to transforming the landscape of immuno-oncology and infectious disease treatment.

Stay informed about ImmunityBio's latest developments, financial performance, and upcoming projects by visiting our news section regularly.

Rhea-AI Summary

ImmunityBio has announced the initiation of a Phase 2b clinical trial for its investigational Tri-Ad5 cancer vaccine, which combines three vaccines with the IL-15 superagonist N-803. This trial aims to assess the effectiveness of this combination in preventing colorectal and other cancers in individuals with Lynch syndrome, a hereditary condition increasing cancer risks. The study will enroll 186 participants across 14 U.S. centers, marking a significant advancement in Lynch syndrome research. Lynch syndrome, which affects about 1 in 300 people, can lead to multiple cancers at a younger age. The Tri-Ad5 vaccines target specific cancer-associated proteins and are designed to enhance immune response.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.69%
Tags
none
-
Rhea-AI Summary

ImmunityBio, Inc. (NASDAQ: IBRX) announces that Executive Chairman Patrick Soon-Shiong, M.D., will deliver the 2023 David Packard Award Lecture at the Uniformed Services University in Bethesda, MD, on April 25. This lecture recognizes his pioneering contributions to cancer therapies and immunotherapy, specifically discussing the activation of natural killer and T cells for cancer treatment. Dr. Soon-Shiong's illustrious career includes significant achievements in immunology and over 500 patents. He founded American Pharmaceutical Partners and developed Abraxane, a groundbreaking chemotherapy drug. The lecture is part of an annual event honoring David Packard, a key figure in U.S. defense and education. ImmunityBio focuses on developing advanced immunotherapies for cancer and infectious diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.69%
Tags
none
-
Rhea-AI Summary

ImmunityBio, Inc. (NASDAQ: IBRX) announced that Dr. Karim Chamie from UCLA will present findings from the QUILT 3.032 study at the ASCO GU conference in San Francisco from February 16-18. This study assesses the quality of life for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving N-803 combined with BCG. Results showed improved physical function among responders and highlighted a favorable risk/benefit ratio. The FDA is reviewing the Biologics License Application for N-803, with a PDUFA date set for May 23, 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.71%
Tags
conferences
Rhea-AI Summary

ImmunityBio, Inc. (NASDAQ: IBRX) has announced a registered direct offering to institutional investors, aiming to raise approximately $50 million in gross proceeds. The financing involves the issuance of common stock and warrants for additional shares, potentially generating up to $60 million if the warrants are fully exercised. This funding is intended to bolster working capital and support ongoing operations. Jefferies LLC acts as the exclusive placement agent for the offering. ImmunityBio is focused on developing innovative immunotherapies targeting cancers and infectious diseases, with its lead candidate N-803 currently under FDA review for bladder cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.42%
Tags
none
-
Rhea-AI Summary

ImmunityBio, identified by NASDAQ: IBRX, announced positive outcomes from its Phase 2 study on metastatic pancreatic cancer, QUILT 88. The study involved 83 patients and showed a median overall survival (OS) of 5.8 months, significantly higher than historical rates of 2-3 months. In the third-line cohort, the median OS reached 6.3 months. Notably, 61% of patients demonstrated disease control. The company held discussions with the FDA regarding registration pathways for pancreatic cancer and NMIBC. A randomized trial is in place for second-line patients, with 25 enrolled to date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
none
-
Rhea-AI Summary

ImmunityBio has secured approximately $50 million in equity financing and $50 million in debt financing from Nant Capital, LLC. The financing also includes a conversion of $56.6 million in debt from NantWorks LLC into equity at a price of $5.67 per share. Furthermore, up to $60 million may be raised through warrants over two years. The funds will be utilized for pre-commercialization, clinical development, and general corporate purposes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.08%
Tags
none
Rhea-AI Summary

LadRx Corporation (OTCQB: LADX) provides a quarterly update for Q3 2022, highlighting its biopharmaceutical advancements, particularly in cancer therapeutics. The company focuses on its LADR technology, enabling targeted chemotherapeutic delivery. Key developments include the next-gen LADR drug candidates LADR7-10 and the progress of Aldoxorubicin, now in clinical trials under Immunity Bio (NASDAQ: IBRX). Financially, LadRx aims to extend its cash runway into mid-2023 while seeking additional funding amidst challenging market conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
none
-
Rhea-AI Summary

ImmunityBio, Inc. (NASDAQ: IBRX) announced its participation in the 34th Annual Piper Sandler Healthcare Conference in New York City from November 29 - December 1, 2022. The presentation is scheduled for November 29 at 2:30 - 2:55 pm EST, featuring a fireside chat with Director and Senior Research Analyst, Joseph Catanzaro, Ph.D. A webcast will be available for those interested. ImmunityBio focuses on developing next-generation immunotherapies and vaccines, currently conducting 27 clinical trials across various cancer and infectious disease indications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
conferences
-
Rhea-AI Summary

ImmunityBio's QUILT 3.032 trial results for N-803 plus BCG show promising efficacy for bladder cancer patients. In the carcinoma in situ cohort, 71% achieved complete response (CR) with a median duration of 26.6 months. The treatment demonstrated a 90% probability of avoiding cystectomy in responders. In the NMIBC cohort, 55% remained disease-free at 12 months. The FDA is reviewing the Biologics License Application for this combination therapy, with a decision expected by May 23, 2023. N-803's safety profile was comparable to BCG alone, indicating its potential role in treating BCG-unresponsive bladder cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.66%
Tags
none
Rhea-AI Summary

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, will present at the Jefferies London Healthcare Conference in London from November 15-17, 2022. The presentation is scheduled for November 15 from 4:25–4:55 PM BST and will include a corporate presentation followed by a Q&A session. A webcast link for the presentation is available online, and a replay will be archived for 90 days. ImmunityBio is focused on developing therapies and vaccines to enhance the immune system against cancers and infectious diseases, with a clinical pipeline of 27 trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
conferences

FAQ

What is the current stock price of ImmunityBio (IBRX)?

The current stock price of ImmunityBio (IBRX) is $5.035 as of November 21, 2024.

What is the market cap of ImmunityBio (IBRX)?

The market cap of ImmunityBio (IBRX) is approximately 3.5B.

What does ImmunityBio, Inc. specialize in?

ImmunityBio specializes in immuno-oncology and infectious disease treatments, focusing on activating both the innate and adaptive immune systems.

What are the key product candidates of ImmunityBio?

Key product candidates include n-803, aldoxorubicin, and Anktiva, an IL-15 superagonist antibody-cytokine fusion protein.

Which cancers does ImmunityBio focus on treating?

ImmunityBio focuses on treating bladder, lung, and colorectal cancers, as well as glioblastoma multiforme (GBM).

What geographical segments does ImmunityBio operate in?

ImmunityBio operates in two geographical segments: the United States and Europe, with key revenue generated from Europe.

What types of therapies is ImmunityBio developing?

ImmunityBio is developing antibody-cytokine fusion proteins, DNA, RNA, and recombinant protein vaccines, as well as cell therapies.

How does ImmunityBio's Anktiva work?

Anktiva is an IL-15 superagonist antibody-cytokine fusion protein that enhances the body's immune response against cancer cells.

What recent achievements has ImmunityBio made?

ImmunityBio has initiated pivotal clinical trials and formed strategic partnerships with leading research institutions.

Where can I find the latest news about ImmunityBio?

You can stay informed about ImmunityBio's latest developments by visiting the news section on our website.

What is ImmunityBio's business model?

ImmunityBio is an integrated biotechnology company involved in discovering, developing, and commercializing immuno- and cellular therapies.

How does ImmunityBio contribute to cancer treatment?

ImmunityBio develops therapies that activate NK cells, T cells, tumoricidal macrophages, and memory T cells to enhance the immune system's ability to fight cancer.

ImmunityBio, Inc.

Nasdaq:IBRX

IBRX Rankings

IBRX Stock Data

3.49B
159.81M
77%
10.11%
7.57%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SAN DIEGO